DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PANACEA BIOTEC LTD (PANACEABIO) share price today?

PANACEA BIOTEC LTD (PANACEABIO) is trading at ₹548.85 on the NSE, down 2.68% on the day. Source: DocStoX.

What is the market capitalisation of PANACEA BIOTEC LTD?

PANACEA BIOTEC LTD has a market capitalisation of approximately ₹3,381 crore.

PANACEA BIOTEC LTD

PANACEABIO·NSE·Healthcare

₹548.85▼ -15.10 (-2.68%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹540.10

₹565.55

52W₹292

₹64772%

Open

₹565.50

High

₹565.55

Low

₹540.10

Prev Close

₹563.95

Volume

2.17L

VWAP

₹549.97

Snapshot

Key fundamentals

Market Cap

₹3,381 Cr

P/E Ratio

N/A

P/B Ratio

4.08

EPS

₹-0.88

Book Value

₹136.00

ROE

-2.36%Weak

ROCE

-2.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.03Low

Face Value

₹1.00

52W High

₹647.00

52W Low

₹292.40

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹112

▼ 79.6%downside

Trading at ₹549 — 80% above our estimate

BearFair valueBull

₹95₹112₹129

/100

Business quality — Watch the fundamentals

Growth 47Profitability 0Efficiency 0Valuation 99

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (-2%)

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Weak returns on equity (-2%)
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

-2% ROE fading to 12% over ~3 yrs, on ₹136 book

₹112

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹112

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Weak returns on equity (-2%)
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-2.4%Weak

Above 15% is considered healthy for Indian equities

ROCE

-2.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.03Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹3,381 Cr

P/B

4.08

EPS

₹-0.88

Div Yield

—

What changed

Recent changes

Foreign investors+0.2% stake last quarter
Domestic institutions+0.1% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Steady

+12% rev CAGR

Profitability

Loss-making

-2.4% ROE

Financial health

Rock solid

D/E 0.03

Momentum

N/A

No technicals

Today

Trading activity

Delivery %37.0%

Turnover₹1195.97L Cr

Trades7,982

VWAP₹549.97

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+11.6%

+0.5%

10Y

-0.2%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

Stock is trading at 4.01 times its book value
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 0.47% over past five years.
Company has a low return on equity of -3.48% over last 3 years.
Earnings include an other income of Rs.36.4 Cr.
Company's cost of borrowing seems high

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.24 pts; domestic institutions added 0.12 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

72%

Promoter

Promoters

72.5%0.00

Public

16.8%-0.68

FII / FPI

1.6%+0.24

DII

2.0%+0.12

Others

7.1%

Total shareholders

32,620-1,977 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.48%

FII1.60%

DII1.97%

Public16.81%

Others7.14%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]